Table 1.
Baseline demographics and disease characteristics
| Characteristic | Risankizumab 150 mg (n = 164) | Secukinumab 300 mg (n = 163) |
|---|---|---|
| Age (years), mean ± SD | 47·3 ± 13·4 | 46·8 ± 14·9 |
| Male, n (%) | 112 (68·3) | 101 (62·0) |
| Race, n (%) | ||
| White | 151 (92·1) | 144 (88·3) |
| Black/African American | 6 (3·7) | 6 (3·7) |
| Asian | 6 (3·7) | 11 (6·7) |
| Other | 1 (0·6) | 2 (1·2) |
| Hispanic or Latino ethnicity, n (%) | 37 (22·6) | 34 (20·9) |
| Bodyweight category, n (%) | ||
| ≤ 100 kg | 112 (68·3) | 109 (66·9) |
| > 100 kg | 52 (31·7) | 54 (33·1) |
| Duration of plaque psoriasis (years), mean ± SD | 18·6 ± 12·6 | 17·4 ± 13·2 |
| sPGA category, n (%) | ||
| 3 | 140 (85·4) | 137 (84·0) |
| 4 | 24 (14·6) | 25 (15·3) |
| < 3 or missing | 0 | 1 (0·6) |
| Body surface area (%), mean ± SD | 23·8 ± 13·8 | 26·0 ± 16·1 |
| PASI, mean ± SD | 19·8 ± 6·3 | 20·1 ± 8·1 |
| Previously used biologics for psoriasis, n (%) | 62 (37·8) | 58 (35·6) |
| IL‐17 inhibitor | 13 (7·9) | 12 (7·4) |
| IL‐23 inhibitor | 3 (1·8) | 2 (1·2) |
| Tumour necrosis factor inhibitor | 38 (23·2) | 38 (23·3) |
| IL‐12/IL‐23 inhibitor | 15 (9·1) | 22 (13·5) |
IL, interleukin; PASI, Psoriasis Area and Severity Index; sPGA, static Physician’s Global Assessment.